Skip to main content
GLP-1 Me

Appetite has a place at this table.

Reading list

The appetite conversation begins with the interviews. The rest of this shelf follows the questions they opened.

Interview accounts

Perceived benefits of treatment for obesity with retatrutide is the starting point for these essays. Its subject is the experience described by phase 2 trial participants. The appetite, eating attitudes and eating behaviours analysis belongs beside it.

I’d begin there before turning to the receptor experiments. Those human descriptions make the biology worth following.

Trials and experiments

The phase 2 obesity trial provides the weight and safety context. The phase 2 diabetes trial concerns people with type 2 diabetes. The structural receptor study and GLP-1 receptor knockout mouse experiment address biological questions at a different scale.

Reviews about craving, mechanisms and durability provide context around the direct studies; the interruption report concerns related treatments.

  1. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. ↗
  2. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide ↗
  3. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial ↗
  4. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial ↗
  5. Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide ↗
  6. GIPR:GCGR co-agonism restores normal weight in obese rodents. ↗
  7. Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? ↗
  8. Mechanisms of GLP-1 in Modulating Craving and Addiction: Neurobiological Insights ↗
  9. Effect of glucagon-like peptide-1 receptor agonists on heart rate in non-diabetic individuals with overweight or obesity: a systematic review and pairwise and network meta-analysis of randomized controlled trials. ↗
  10. Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption ↗
  11. Obesity pharmacotherapy reimagined: The era of multi-receptor agonists and next-generation metabolic modulators, perspectives and controversies. ↗
  12. The First Triple Agonist for Antiobesity: Retatrutide ↗